中山莱博瑞辰

Lab-Ray is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for bone and joint diseases. The company utilizes a proprietary bone-targeting technology platform to design drugs with high affinity for bone tissue, aiming to improve efficacy while reducing systemic side effects. Its lead candidate, LR004, is a bone-targeting parathyroid hormone (PTH) analog currently in clinical trials for the treatment of osteoporosis. Lab-Ray's pipeline also includes programs for osteoarthritis, bone metastasis, and rare bone disorders. Headquartered in Zhongshan, China, the company integrates R&D, clinical development, and future manufacturing capabilities to address significant unmet needs in skeletal health.